Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia
<div><p>The exponential expansion of genomic data coupled with the lack of appropriate clinical categorization of the variants is posing a major challenge to conventional medications for many common and rare diseases. To narrow this gap and achieve the goals of personalized medicine, a c...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , |
| منشور في: |
2021
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513516569886720 |
|---|---|
| author | Nagham N. Hindi (18526815) |
| author2 | Jamil Alenbawi (14056978) Georges Nemer (295984) |
| author2_role | author author |
| author_facet | Nagham N. Hindi (18526815) Jamil Alenbawi (14056978) Georges Nemer (295984) |
| author_role | author |
| dc.creator.none.fl_str_mv | Nagham N. Hindi (18526815) Jamil Alenbawi (14056978) Georges Nemer (295984) |
| dc.date.none.fl_str_mv | 2021-08-31T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.3390/jpm11090877 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Pharmacogenomics_Variability_of_Lipid-Lowering_Therapies_in_Familial_Hypercholesterolemia/25779825 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biological sciences Genetics familial hypercholesterolemia pharmacogenomics PCSK9 inhibitors statins ezetimibe novel lipid-lowering therapy |
| dc.title.none.fl_str_mv | Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <div><p>The exponential expansion of genomic data coupled with the lack of appropriate clinical categorization of the variants is posing a major challenge to conventional medications for many common and rare diseases. To narrow this gap and achieve the goals of personalized medicine, a collaborative effort should be made to characterize the genomic variants functionally and clinically with a massive global genomic sequencing of “healthy” subjects from several ethnicities. Familial-based clustered diseases with homogenous genetic backgrounds are amongst the most beneficial tools to help address this challenge. This review will discuss the diagnosis, management, and clinical monitoring of familial hypercholesterolemia patients from a wide angle to cover both the genetic mutations underlying the phenotype, and the pharmacogenomic traits unveiled by the conventional and novel therapeutic approaches. Achieving a drug-related interactive genomic map will potentially benefit populations at risk across the globe who suffer from dyslipidemia.</p><p> </p></div><h2>Other Information</h2> <p> Published in: Journal of Personalized Medicine<br> License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/jpm11090877" target="_blank">https://dx.doi.org/10.3390/jpm11090877</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_a081037cdd76e82cae8a408b7a7c8ebf |
| identifier_str_mv | 10.3390/jpm11090877 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25779825 |
| publishDate | 2021 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial HypercholesterolemiaNagham N. Hindi (18526815)Jamil Alenbawi (14056978)Georges Nemer (295984)Biological sciencesGeneticsfamilial hypercholesterolemiapharmacogenomicsPCSK9 inhibitorsstatinsezetimibenovel lipid-lowering therapy<div><p>The exponential expansion of genomic data coupled with the lack of appropriate clinical categorization of the variants is posing a major challenge to conventional medications for many common and rare diseases. To narrow this gap and achieve the goals of personalized medicine, a collaborative effort should be made to characterize the genomic variants functionally and clinically with a massive global genomic sequencing of “healthy” subjects from several ethnicities. Familial-based clustered diseases with homogenous genetic backgrounds are amongst the most beneficial tools to help address this challenge. This review will discuss the diagnosis, management, and clinical monitoring of familial hypercholesterolemia patients from a wide angle to cover both the genetic mutations underlying the phenotype, and the pharmacogenomic traits unveiled by the conventional and novel therapeutic approaches. Achieving a drug-related interactive genomic map will potentially benefit populations at risk across the globe who suffer from dyslipidemia.</p><p> </p></div><h2>Other Information</h2> <p> Published in: Journal of Personalized Medicine<br> License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/jpm11090877" target="_blank">https://dx.doi.org/10.3390/jpm11090877</a></p>2021-08-31T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.3390/jpm11090877https://figshare.com/articles/journal_contribution/Pharmacogenomics_Variability_of_Lipid-Lowering_Therapies_in_Familial_Hypercholesterolemia/25779825CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/257798252021-08-31T03:00:00Z |
| spellingShingle | Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia Nagham N. Hindi (18526815) Biological sciences Genetics familial hypercholesterolemia pharmacogenomics PCSK9 inhibitors statins ezetimibe novel lipid-lowering therapy |
| status_str | publishedVersion |
| title | Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia |
| title_full | Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia |
| title_fullStr | Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia |
| title_full_unstemmed | Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia |
| title_short | Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia |
| title_sort | Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia |
| topic | Biological sciences Genetics familial hypercholesterolemia pharmacogenomics PCSK9 inhibitors statins ezetimibe novel lipid-lowering therapy |